Latest Developments in Global Menieres Disease Drug Market

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Latest Developments in Global Menieres Disease Drug Market

  • Pharmaceutical
  • Upcoming Report
  • Nov 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

  • In August 2024, Sound Pharmaceuticals has completed the Phase III STOPMD-3 trial of SPI-1005, an investigational anti-inflammatory for Meniere's disease, marking the longest treatment study for hearing loss or tinnitus, with subjects initially in a three-month RCT, followed by a six-month open-label extension (OLE) and an optional additional six months
  • In July 2023, Spiral Therapeutics has secured USD 8.25 billion in investor funding to advance Phase 2 development of its sustained-release steroid candidate for treating a debilitating inner ear disorder. The company is focusing this technology on Meniere’s disease a rare inner ear condition causing vertigo, tinnitus, and hearing loss by delivering dexamethasone through precise, sustained-release injections directly into the ear

Frequently Asked Questions

The market is segmented based on Global Meniere’s Disease Drug Market Segmentation, By  Type (Classic, Vestibular, and Bilateral), Mechanism of Action (Antihistamines, Benzodiazepines, Antinausea, Diuretics, Antibiotics, Steroids, and Others), Drugs (Meclizine, Diazepam, Prochlorperazine, Hydrochlorothiazide, Gentamicin, Dexamethasone, and Others), Devices (Hearing Aid and Meniett device), Treatment (Medications, Therapy or Hearing Aids, and Surgery), Route of Administration (Oral, Intravenous, Intratympanic, and Others), Distribution Channel (Online Pharmacy, Direct Tenders, Retailers, and Others), End Users (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2032 .
The Global Menieres Disease Drug Market size was valued at USD 345.92 USD Million in 2024.
The Global Menieres Disease Drug Market is projected to grow at a CAGR of 9.9% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.